AU2002317105A1 - Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors - Google Patents

Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Info

Publication number
AU2002317105A1
AU2002317105A1 AU2002317105A AU2002317105A AU2002317105A1 AU 2002317105 A1 AU2002317105 A1 AU 2002317105A1 AU 2002317105 A AU2002317105 A AU 2002317105A AU 2002317105 A AU2002317105 A AU 2002317105A AU 2002317105 A1 AU2002317105 A1 AU 2002317105A1
Authority
AU
Australia
Prior art keywords
wnt
methods
therapeutic agents
treating diseases
diseases involving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002317105A
Other languages
English (en)
Inventor
Yigal P. Goldberg
Michael R. Hayden
Marcia L. Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Xenon Pharmaceuticals Inc
Original Assignee
University of British Columbia
Xenon Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Xenon Genetics Inc filed Critical University of British Columbia
Publication of AU2002317105A1 publication Critical patent/AU2002317105A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002317105A 2001-07-05 2002-07-05 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors Abandoned AU2002317105A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US30328501P 2001-07-05 2001-07-05
US60/303,285 2001-07-05
US34040901P 2001-10-29 2001-10-29
US60/340,409 2001-10-29
US36035202P 2002-02-28 2002-02-28
US60/360,352 2002-02-28
PCT/CA2002/001016 WO2003004045A2 (fr) 2001-07-05 2002-07-05 Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt

Publications (1)

Publication Number Publication Date
AU2002317105A1 true AU2002317105A1 (en) 2003-01-21

Family

ID=27404928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317105A Abandoned AU2002317105A1 (en) 2001-07-05 2002-07-05 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Country Status (2)

Country Link
AU (1) AU2002317105A1 (fr)
WO (1) WO2003004045A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2004020668A2 (fr) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Methode de traitement du synovialome
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2005025590A2 (fr) * 2003-09-15 2005-03-24 Develogen Aktiengesellschaft Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques
WO2006130076A1 (fr) * 2005-05-30 2006-12-07 Astrazeneca Ab Procedes permettant d'identifier des modulateurs fzd8 et utilisation de ces modulateurs pour traiter l'osteoarthrite
WO2007030658A2 (fr) 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions et methodes utilisees pour moduler l'angiogenese
CA2628116A1 (fr) 2005-10-31 2007-12-13 Oncomed Pharmaceuticals, Inc. Compositions et procedes de diagnostic et de traitement du cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN101365945A (zh) * 2006-02-07 2009-02-11 惠氏公司 用于鉴别调节诺里蛋白、诺里蛋白模拟物的药剂的物质和方法以及由此鉴别出的药剂
RU2412203C2 (ru) 2006-06-21 2011-02-20 Онкотерапи Сайенс, Инк. Направленные на опухоль моноклональные антитела против fzd10 и их применение
CA2662041A1 (fr) 2006-09-08 2008-03-13 Genentech, Inc. Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
WO2011050096A2 (fr) 2009-10-21 2011-04-28 Retinal Solutions Llc Méthodes et compositions utilisées pour le diagnostic et le traitement d'une rétinopathie génétique
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (fr) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux recepteurs frizzled et leurs utilisations
EP3281640A1 (fr) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
WO2014066328A1 (fr) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
CN111394453A (zh) * 2020-05-11 2020-07-10 四川省人民医院 检测与fevr相关的致病基因突变的引物组、试剂盒和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (fr) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS A BASE DU RECEPTEUR DE Wnt ET PROCEDES D'UTILISATION DE CELLES-CI
WO1999026960A2 (fr) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes codant des proteines ressemblant a de la frisee
GB9819681D0 (en) * 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
WO2003004045A2 (fr) 2003-01-16
WO2003004045A3 (fr) 2003-05-30

Similar Documents

Publication Publication Date Title
AU2002317105A1 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
IL161327A0 (en) Methods for treating ocular neovascular diseases
GB0111872D0 (en) Therapeutic agents and methods
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
IL160933A0 (en) Methods and compositions for treating ?cap associated diseases
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002303283A1 (en) Methods for treating drug addiction
GB0123951D0 (en) Therapies for treating respiratory diseases
AU2002346504A8 (en) Therapeutic protein and treatments
EP1463527A4 (fr) Utilisation de gammaglobuline pour le traitement de maladies d'origine immunologique
EP1534310A4 (fr) Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies
AU2002353777A1 (en) Saliva-based methods for preventing and assessing the risk of diseases
EP1463495A4 (fr) Agents et procedes de traitement du cancer
AU2003216524A1 (en) Methods for inducing vascular remodeling and related methods for treating diseased vascular structures
EP1558238A4 (fr) Beta-hydroxyphenylaldylamines et utilisation de celles-ci pour traiter le glaucome
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
HK1066742A1 (en) Use of desoxypeganine for treating clinical depression
AU2002341828A1 (en) Enhanced proteins and methods for their use
HUP0400066A2 (hu) Eljárás és eszköz gluténindukált betegségek kimutatására
AU2003284166A1 (en) Methods for diagnosing and treating pre-term labor
IL151648A0 (en) Method for photodynamic therapy and applicator for carrying out said therapy
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003256209A1 (en) Use of human protein kinase c-eta in methods for identification of pharmaceutically useful agents
AU2003293581A1 (en) Method of identifying therapeutic agents
AU2002328905A1 (en) A method for determining the therapeutic effectiveness of a substance using a microphysiometer and use of the method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase